Environmentally responsive anticoagulant fusion protein rHTA and application thereof

By designing the fusion protein rHTA, Hirudin and AnxV are activated locally at the thrombus through the thrombin cleavage site, achieving highly efficient anticoagulation and low bleeding risk thrombosis treatment, thus solving the problems of short half-life and easy bleeding associated with hirudin drugs.

CN120887998APending Publication Date: 2025-11-04BEIJING NORMAL UNIVERSITY
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202511024266.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-07-24
Publication Date
2025-11-04

AI Technical Summary

Technical Problem

Existing hirudin-based anticoagulants are metabolized rapidly in the body, have short half-lives, and are prone to causing bleeding risks, making it difficult to achieve efficient anticoagulation and safe thrombosis treatment.

Method used

A fusion protein rHTA was designed, which contains Hirudin protein, thrombin cleavage site and AnxV protein. It is activated locally by thrombin in the thrombus and releases AnxV protein and Hirudin protein, so as to achieve targeted enrichment and local precise anticoagulation.

Benefits of technology

The fusion protein rHTA accumulates and releases anticoagulants at the thrombus formation site, significantly enhancing anticoagulant efficacy, reducing bleeding risk, and providing an efficient, long-lasting, and safe anticoagulant therapy.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005515493880000021
    Figure BDA0005515493880000021
  • Figure BDA0005515493880000031
    Figure BDA0005515493880000031
  • Figure HDA0005515493900000011
    Figure HDA0005515493900000011
Patent Text Reader

Abstract

The invention discloses a fusion protein rHTA and application thereof, the fusion protein rHTA is sequentially composed of a Hirudin protein, a thrombin cleavage site and an AnxV protein from the N terminal to the C terminal, and the amino acid sequence is as shown in SEQ ID NO: 4 from the 1st site to the 393th site from the N terminal. Experiments prove that the fusion protein rHTA is specifically activated by thrombin at the local part of thrombus and releases AnxV protein and Hirudin protein, and the AnxV protein can specifically recognize and combine with PS, so that the fusion protein rHTA is enriched at the thrombosis part containing platelets in a targeted manner, the Hirudin protein is locally released under the action of thrombin, local precise anticoagulation is realized, and the anticoagulation efficiency is further enhanced. Therefore, the fusion protein rHTA provided by the invention not only has high anticoagulant activity, but also realizes enrichment and release at the thrombus formation part, and reduces the bleeding risk. The method has an important application value.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] The present application belongs to the field of biomedicine, and particularly relates to an environment-responsive anticoagulant fusion protein rHTA and application thereof. BACKGROUND

[0002] Thrombotic diseases (such as atherosclerosis, coronary heart disease, cerebral infarction, etc.) are major diseases threatening human health, with high morbidity, and the prevention and treatment research has been a hot spot in the medical field (Goto S, Tomita A. Antithrombotic Therapy for Prevention of Various Thrombotic Diseases [J]. Drug Development Research, 2013, 74 (8): 568-574. Nigel M, Wolfgang B, A G S, et al. Therapeutic strategies for thrombosis: new targets and approaches. [J]. Nature reviews. Drug discovery, 2020, 19 (5): 333-352.).

[0003] Hirudin is a highly effective and specific natural thrombin inhibitor, which can form a stable complex with thrombin at a ratio of 1:1, thus having a highly specific inhibitory effect on thrombin and exerting anticoagulant activity (Wang H L, Wang L Z. The basis and clinical of hirudin [J]. Shanghai Medicine, 1999(11): 695-697). Hirudin drugs have shown great clinical application value in the prevention and treatment of thrombotic diseases (Norbert L, Andreas G. Hirudin in heparin-induced thrombocytopenia. [J]. Seminars in thrombosis and hemostasis, 2002, 28(5): 431-8.). However, as a small molecule protein drug, Hirudin has the disadvantages of fast metabolism and short half-life in vivo, and its inhibition of thrombin in vivo is relatively extensive, which may cause bleeding risk in clinical use (Zhang C L, Yu A P, Jin J D, et al. Research progress of hirudin fusion protein [J]. Chinese Journal of Experimental Hematology, 2007, (01): 215-218.). How to better exert the anticoagulant advantage of Hirudin and make up for its short half-life and bleeding risk is one of the current research hotspots (Zhao B, Zhang Y, Huang Y, et al. A novel hirudin derivative inhibiting thrombin without bleeding for subcutaneous injection [J]. Thromb Haemost, 2017, 117(1): 44-56).

[0004] Annexin A5 (AnxV) is a protein with platelet binding activity. When platelets are activated, the phosphatidylserine (L-A-Phosphatidyl-L-serine, PS; a procoagulant factor) of the plasma membrane is everted, AnxV can compete with some procoagulant factors (Va, Xa and prothrombin, etc.) to bind PS, which makes PS, a procoagulant factor, isolated from other related procoagulant factors, inhibits the formation of prothrombin complex and thrombin, etc., thereby achieving the effect of anticoagulation (Wahezi D, Ilowitz N, Wu X, et al. Annexin A5 anticoagulant activity in children with systemic lupus erythematosus and the association with antibodies to domain I of β2-glycoprotein I [J]. Lupus, 2013, 22(7): 702-711. Paul A, Xiangru L, Fatemeh A, et al. Recombinant human annexin A5 inhibits proinflammatory response and improves cardiac function and survival in mice with endotoxemia. [J]. Critical care medicine, 2014, 42(1): e32-41. Zhang Xirui, Jing Jian. Cloning and detection of human placental annexin V cDNA. Journal of Beijing Normal University (Natural Science Edition), 2007, 43(4): 438-441. Liang Papan, Zhang Xirui, Jing Jian. Preliminary study on expression and properties of human annexin. Journal of Beijing Normal University (Natural Science Edition), 2009, 45(4): 378-380.). The targeting specificity of AnxV to PS and its anticoagulant properties make it a guide agent for selectively targeting platelet-containing thrombus, and it is an effective candidate for constructing potential recombinant protein drugs (Zhang Qian, Meng Qingyu, Jing Jian. Human annexin A5: from biomarker to drug candidate [J]. Chinese Journal of Biochemistry and Molecular Biology, 2022, 38(10): 1311-1321. DOI: 10.13865 / j.cnki.cjbmb.2022.01.1506.). SUMMARY

[0005] The purpose of the present application is to provide an anticoagulant drug with high anticoagulant effect and low risk of bleeding.

[0006] The present application first protects a fusion protein, which is named fusion protein rHTA, and can sequentially comprise a Hirudin protein, a thrombin cleavage site and an AnxV protein from N terminus to C terminus;

[0007] The amino acid sequence of the Hirudin protein can be as shown in SEQ ID NO: 4 from 1 to 66 from N terminus.

[0008] The amino acid sequence of the AnxV protein can be as shown in SEQ ID NO: 4 from 73 to 393 from N terminus.

[0009] In the above-mentioned fusion protein, the amino acid sequence of the thrombin cleavage site can be as shown in SEQ ID NO: 4 from 67 to 72 from N terminus.

[0010] Any of the above-mentioned fusion proteins can sequentially consist of a Hirudin protein, a thrombin cleavage site and an AnxV protein from N terminus to C terminus.

[0011] Any of the above-mentioned fusion proteins can be a1) or a2) or a3):

[0012] a1) the amino acid sequence is a protein as shown in SEQ ID NO: 4 from 1 to 393 from N terminus;

[0013] a2) a fusion protein obtained by connecting a tag to the N terminus or / and C terminus of the protein as shown in a1);

[0014] a3) a protein having the effects of anticoagulation, inhibition of thrombin, improvement of anticoagulant activity and / or prevention of thrombotic diseases, which is obtained by substitution and / or deletion and / or addition of one or several amino acid residues to the protein as shown in a1) or a2).

[0015] In order to facilitate the purification of the protein in a1), a tag as shown in Table 1 can be connected to the amino terminus or carboxyl terminus of the protein as shown in a1).

[0016] Table 1. Sequence of the tag

[0017]

[0018]

[0019] The amino acid sequence of the protein in a2) can be as shown in SEQ ID NO: 4.

[0020] In the fusion protein in a3), the substitution and / or deletion and / or addition of one or several amino acid residues is substitution and / or deletion and / or addition of no more than 10 amino acid residues.

[0021] The fusion protein in a3) above can be artificially synthesized, or a gene encoding the same can be synthesized and expressed biologically.

[0022] The gene encoding the fusion protein in a3) above can be obtained by deleting one or more codons of the DNA sequence shown in SEQ ID NO: 1, and / or performing one or more base pair missense mutations, and / or connecting the coding sequence of the tag shown in Table 1 to the 5' end and / or 3' end thereof.

[0023] The present application also protects a nucleic acid molecule encoding any of the above-described fusion proteins.

[0024] In the above-described nucleic acid molecule, the nucleotide sequence encoding the Hirudin protein is shown in SEQ ID NO: 1 from the 1st to 198th position from the 5' end. The nucleotide sequence encoding the AnxV protein is shown in SEQ ID NO: 1 from the 217th to 1179th position from the 5' end. The nucleotide sequence encoding the thrombin cleavage site is shown in SEQ ID NO: 1 from the 199th to 216th position from the 5' end.

[0025] Any of the above-described nucleic acid molecules can be a DNA molecule as shown in e1) or e2) or e3) or e4) or e5) below:

[0026] e1) the nucleotide sequence is a DNA molecule shown in SEQ ID NO: 1;

[0027] e2) the nucleotide sequence is a DNA molecule shown in SEQ ID NO: 1 from the 1st to 1179th position from the 5' end;

[0028] e3) the nucleotide sequence is a DNA molecule shown in SEQ ID NO: 1 from the 1st to 1197th position from the 5' end;

[0029] e4) a DNA molecule having 75% or more identity to the nucleotide sequence defined in e1) or e2) or e3), and encoding any of the above-described fusion proteins;

[0030] e5) a DNA molecule hybridizing to the nucleotide sequence defined in e1) or e2) or e3) under stringent conditions, and encoding any of the above-described fusion proteins.

[0031] The DNA molecule having the nucleotide sequence shown in SEQ ID NO: 1 from the 1st to 1197th position from the 5' end encodes the fusion protein having the amino acid sequence shown in SEQ ID NO: 4.

[0032] An expression cassette, a recombinant vector, or a recombinant microorganism containing any of the above-described nucleic acid molecules encoding any of the above-described fusion proteins also falls within the scope of the present application.

[0033] The application also protects the use of any of the above-mentioned fusion proteins, any of the above-mentioned nucleic acid molecules or the expression cassette, recombinant vector or recombinant microorganism containing any of the above-mentioned nucleic acid molecules in the preparation of a product; the function of the product can be anticoagulation, inhibition of thrombin, improvement of antithrombin activity and / or prevention of thrombotic diseases.

[0034] In the above-mentioned application, the product can be a drug.

[0035] The drug can be a targeted anticoagulant drug. The targeting can be targeting platelet-containing thrombus.

[0036] The use of any of the above-mentioned fusion proteins as a thrombin inhibitor or an anticoagulant also falls within the protection scope of the application.

[0037] The use of any of the above-mentioned nucleic acid molecules or the expression cassette, recombinant vector or recombinant microorganism containing any of the above-mentioned nucleic acid molecules in the preparation of a thrombin inhibitor or an anticoagulant also falls within the protection scope of the application.

[0038] In any of the above-mentioned applications, the anticoagulant can be an anticoagulant drug.

[0039] In the above-mentioned application, the anticoagulant drug can target platelet-containing thrombus.

[0040] The anticoagulation can be in vitro anticoagulation and / or in vivo anticoagulation.

[0041] Based on the limitations of existing anticoagulant drugs, such as narrow safety window and high risk of bleeding, the inventors of the present application prepared a fusion protein rHTA (Hirudin-speical thrombin site-AnxV) through a large number of experiments. By introducing a thrombin cleavage site, the fusion protein rHTA is specifically activated by thrombin at the thrombus site, releasing AnxV protein and Hirudin protein. AnxV protein can specifically recognize and bind to PS, so that the fusion protein rHTA is targeted to the thrombus site containing platelets, and Hirudin protein is released locally under the action of thrombin, realizing local precise anticoagulation and further enhancing the anticoagulant effect. At the same time, the anticoagulant properties of the fusion protein rHTA were evaluated in multiple aspects, and the results are as follows: the anticoagulant activity of the fusion protein rHTA is significantly enhanced after thrombin cleavage, and is concentration-dependent, the antithrombin activity is significantly improved, the inhibition constant (Ki) is 2.120 nM, and it shows a dose-dependent anticoagulant effect in plasma recalcification experiment. The fusion protein rHTA provided by the present application realizes enrichment and release at the thrombus formation site, reduces the risk of bleeding, provides a basis for developing an anticoagulant with high efficiency, long half-life (i.e. slow release) and low risk of bleeding, and has important application value. BRIEF DESCRIPTION OF DRAWINGS

[0042] Figure 1 SDS-PAGE detection results of induced expression and nickel column purification of fusion protein rHTA in Example 1.

[0043] Figure 2 Analysis of cleavage effect of thrombin on fusion protein rHTA in Example 2.

[0044] Figure 3 Phospholipid binding analysis results of fusion protein rHTA in Example 3.

[0045] Figure 4 Effect of fusion protein rHTA on plasma clotting time in Example 4.

[0046] Figure 5 Evaluation of effect of fusion protein rHTA on thrombin in Example 5.

[0047] Figure 6 Effect of fusion protein rHTA on activated partial thromboplastin time (APTT) in Example 6.

[0048] Figure 7 Flow cytometry detection results of controls in platelet binding experiment of Example 7.

[0049] Figure 8 Flow cytometry detection results of 1000 nM of FITC-labeled fusion protein HA in platelet binding experiment of Example 7.

[0050] Figure 9 Flow cytometry detection results of 1000 nM of FITC-labeled fusion protein HA in platelet binding experiment of Example 7.

[0051] Figure 10 Flow cytometry detection results of 1000 nM of FITC-labeled fusion protein HA in platelet binding experiment of Example 7.

[0052] Figure 11 Flow cytometry detection results of 1000 nM of FITC-labeled fusion protein rHTA in platelet binding experiment of Example 7.

[0053] Figure 12 Flow cytometry detection results of 1000 nM of FITC-labeled fusion protein rHTA in platelet binding experiment of Example 7.

[0054] Figure 13 Flow cytometry detection results of 1000 nM of FITC-labeled fusion protein rHTA in platelet binding experiment of Example 7.

[0055] Figure 14Statistical results of fluorescence intensity of platelets in the platelet binding experiment of Example 7. DETAILED DESCRIPTION

[0056] The application will be further described in conjunction with the specific embodiments. The examples provided below are only for the purpose of illustrating the application, and are not intended to limit the scope of the application. The examples provided below can serve as a guide for further improvement by those skilled in the art, and do not in any way constitute a limitation on the application.

[0057] In the following examples, the experimental methods are conventional methods, and are performed according to the techniques or conditions described in the literature in the art or according to the product instructions, unless otherwise specified. The materials, reagents, etc. used in the following examples can be obtained commercially, unless otherwise specified.

[0058] In the quantitative test in the following examples, three repeated experiments are set, and the average value is taken.

[0059] In the following examples, thrombin is a product of Sigma-Aldrich Company, and the product catalog number is T6884.

[0060] Example 1, expression and purification of fusion protein rHTA

[0061] I. Construction of recombinant plasmid

[0062] 1. Construction of recombinant plasmid pETX-rHTA

[0063] The DNA fragment between the restriction enzymes NcoI and XhoI of the pETX vector (purchased from Thermo Fisher (Invitrogen) Company) is replaced by a DNA molecule with the nucleotide sequence shown in SEQ ID NO: 1 to obtain the recombinant plasmid pETX-rHTA.

[0064] The recombinant plasmid pETX-rHTA expresses the fusion protein rHTA, and the amino acid sequence of the fusion protein rHTA is shown in SEQ ID NO: 4. The fusion protein rHTA includes, in order from the N-terminal to the C-terminal, a Hirudin protein, a thrombin cleavage site, an AnxV protein and a His tag; the amino acid sequence of the Hirudin protein is shown in SEQ ID NO: 4 from the 1st to the 66th from the N-terminal; the amino acid sequence of the thrombin cleavage site is shown in SEQ ID NO: 4 from the 67th to the 72nd from the N-terminal; the amino acid sequence of the AnxV protein is shown in SEQ ID NO: 4 from the 73rd to the 393rd from the N-terminal; and the amino acid sequence of the His tag is shown in SEQ ID NO: 4 from the 394th to the 399th from the N-terminal.

[0065] 2. Construction of recombinant plasmid pETX-HA

[0066] The DNA molecule with nucleotide sequence as shown in SEQ ID NO: 2 is used to replace the small DNA fragment between restriction enzymes Ncol and Xhol of pETX vector, to obtain recombinant plasmid pETX-HA.

[0067] The recombinant plasmid pETX-HA expresses fusion protein HA, and the amino acid sequence of fusion protein HA is shown in SEQ ID NO: 5. Fusion protein HA comprises, from N-terminus to C-terminus, Hirudin protein, connecting peptide, AnxV protein and His tag; the amino acid sequence of Hirudin protein is shown in SEQ ID NO: 5 from 1st to 66th from N-terminus; the amino acid sequence of connecting peptide is shown in SEQ ID NO: 5 from 67th to 70th from N-terminus; the amino acid sequence of AnxV protein is shown in SEQ ID NO: 5 from 71st to 391st from N-terminus; and the amino acid sequence of His tag is shown in SEQ ID NO: 5 from 392nd to 397th from N-terminus.

[0068] 3. Construction of recombinant plasmid pETX-AnxV

[0069] The DNA molecule with nucleotide sequence as shown in SEQ ID NO: 3 is used to replace the small DNA fragment between restriction enzymes Ncol and Xhol of pETX vector, to obtain recombinant plasmid pETX-AnxV.

[0070] The recombinant plasmid pETX-AnxV expresses AnxV protein, and the amino acid sequence of AnxV protein is shown in SEQ ID NO: 6.

[0071] It should be noted that, considering that both fusion protein rHTA and fusion protein HA are fusion proteins, the AnxV protein in fusion protein rHTA and fusion protein HA both have the first amino acid, methionine, removed.

[0072] II. Induced expression and nickel column purification of fusion protein rHTA

[0073] 1. The recombinant plasmid pETX-rHTA is transformed into E. coli BL21(DE3) to obtain recombinant E. coli containing recombinant plasmid pETX-rHTA, which is named BL21(DE3) / pETX-rHTA. The pETX vector is transformed into E. coli BL21(DE3) to obtain recombinant E. coli containing pETX vector, which is named BL21(DE3) / pETX, as a negative control.

[0074] 2. After completing step 1, inoculate a single clone of recombinant Escherichia coli (BL21(DE3) / pETX-rHTA or BL21(DE3) / pETX) into 5 mL of LB liquid medium (Kan). + The culture was incubated overnight at 37°C and 190 rpm to obtain culture solution 1; culture solution 1 was then inoculated into 500 mL of TM medium (Kan + ), incubated at 37℃ and 190rpm, to obtain OD 600nm The culture medium was approximately 0.6 g / L.

[0075] 3. After completing step 2, add IPTG solution (solvent is water) or water (as a blank control) to culture culture 2 to obtain the induction system (the concentration of IPTG in the induction system is 100 μM); then incubate at 16℃ for 10 h to obtain culture culture 3.

[0076] 4. After completing step 3, the culture medium 3 is sonicated and the supernatant is collected. The supernatant is subjected to 12% SDS-PAGE to detect the induction efficiency and specificity of the fusion protein rHTA.

[0077] Test results are shown Figure 1 In Figure A (pETX-HTA is the recombinant plasmid pETX-rHTA, pETX is the pETX vector, + indicates IPTG induction, - indicates no IPTG induction), the results showed that a new protein band appeared near 40 kDa in the recombinant plasmid pETX-rHTA, which is consistent with the theoretical molecular weight of the fusion protein rHTA (42.7 kDa). Compared with no IPTG induction, the protein band near 40 kDa was more obvious after IPTG induction. Therefore, the recombinant plasmid pETX-rHTA successfully expressed the fusion protein rHTA, and the induction expression efficiency and specificity of the fusion protein rHTA were both high.

[0078] 5. After completing step 3, take the cultured bacterial solution 3, centrifuge, and collect the bacterial precipitate; then resuspend 1g of bacterial precipitate in 20mL of lysis buffer (dissolve 6.8g of Tris, 11.7g of NaCl, and 100μL of glycerol in an appropriate amount of distilled water, then bring the volume to 1L with distilled water and adjust the pH to 7.4), and sonicate on ice (600W, 3s / 27s, 60 cycles); collect the supernatant after centrifugation, filter it through a filter membrane, and load it onto a pre-equilibrated nickel column (flow rate 0.5mL / min); after washing, perform gradient elution with 10mM imidazole solution, 25mM imidazole solution, and 50mM imidazole solution (flow rate 0.5mL / min), collect the eluent and dialyze overnight at 4℃, and analyze by 12% SDS-PAGE electrophoresis.

[0079] Test results are shown Figure 1Middle B (elution 1 was eluted with 10 mM imidazole solution, elution 2 was eluted with 25 mM imidazole solution, and elution 3 was eluted with 50 mM imidazole solution gradient). The detection results showed that after nickel column purification, PAGE electrophoresis showed a protein band near 40 kDa, which was basically consistent with the theoretical value of 42.7 kDa.

[0080] It can be seen that the eluate is the purified fusion protein rHTA. The eluate collected after elution with 50 mM imidazole solution was used for subsequent experiments.

[0081] III. Expression and purification of fusion protein HA and AnxV protein

[0082] According to the method of step two above, replace the recombinant plasmid pETX-rHTA with the recombinant plasmid pETX-HA, and the other steps remain unchanged to obtain the fusion protein HA.

[0083] According to the method of step two above, replace the recombinant plasmid pETX-rHTA with the recombinant plasmid pETX-AnxV, and the other steps remain unchanged to obtain the AnxV protein.

[0084] Example 2, thrombin cleavage sensitivity detection

[0085] Cleavage Buffer was prepared according to the method in the reference (Xiudong W, Guangman Z, Lisheng W, et al. A fusion protein with improved thrombolytic effect and low bleeding risk. [J]. Thrombosis and haemostasis, 2009, 102(6): 1194-203.) by the inventors of the present application.

[0086] To detect whether the fusion protein rHTA can be effectively cleaved by thrombin and evaluate its cleavage efficiency, thrombin cleavage sensitivity detection experiment was performed. The molecular weight of the fusion protein rHTA is about 42.7 kDa, which should be theoretically cleaved by thrombin into AnxV protein (molecular weight about 35.8 kDa) and Hirudin protein (molecular weight about 7 kDa) two fragments. Specifically, the thrombin cleavage sensitivity of the fusion protein rHTA was detected according to the method in the reference (Zhang Q, Meng QY, Jing J. Human annexin A5: from biomarker to drug candidate [J]. Chinese Journal of Biochemistry and Molecular Biology, 2022, 38(10): 1311-1321. DOI: 10.13865 / j.cnki.cjbmb.2022.01.1506.). Specifically as follows:

[0087] 1、Set five control groups and seven experimental groups, as follows:

[0088] Seven experimental groups: 70 μL thrombin (concentration of 1000 U / mL), 350 μL fusion protein rHTA (concentration of 2.5 mg / mL) were mixed, then supplemented with Cleavage Buffer to 700 μL, mixed evenly, and then divided into 7 parts, each part was 1 reaction system. Respectively, 7 reaction systems were taken, and 37℃ reaction was carried out for 30s, 5min, 30min, 1h, 3h, 6h and 12h.

[0089] Control group ①, i.e. rHTA group without incubation: 10 μL thrombin (concentration of 1000 U / mL) was added with Cleavage Buffer to 100 μL, and 37℃ reaction was carried out for 6h.

[0090] Control group ②, i.e. rHTA group incubated for 6h: 10 μL thrombin (concentration of 1000 U / mL), 50 μL fusion protein rHTA (concentration of 2.5 mg / mL) were mixed, then supplemented with Cleavage Buffer to 100 μL, mixed evenly, and then reacted at room temperature for 6h.

[0091] Control group ③, i.e. AnxV group: 10 μL thrombin (concentration of 1000 U / mL), 50 μL AnxV protein prepared in Example 1 (concentration of 2.5 mg / mL) were mixed, then supplemented with Cleavage Buffer to 100 μL, mixed evenly, and then reacted at 37℃ for 6h.

[0092] Control group ④, i.e. thrombin group: 100 μL thrombin (concentration of 1000 U / mL) was taken, and 37℃ reaction was carried out for 6h.

[0093] Control group ⑤, i.e. Cleavage Buffer group: 100 μL Cleavage Buffer was taken, and 37℃ reaction was carried out for 6h.

[0094] 2、After completing step 1, sample preparation, 12% SDS-PAGE electrophoresis detection analysis.

[0095] The detection results are shown in Figure 2(HTA is fusion protein rHTA, ANV is AnxV protein). The detection results show that under the action of thrombin, the expected AnxV protein fragment of the fusion protein rHTA begins to appear at 30 min, and the amount of the AnxV protein fragment increases significantly within 3-12 h, and the AnxV protein is completely cut at 12 h. It can be seen that the fusion protein rHTA is gradually cut under the action of thrombin, and the cutting efficiency increases with time. This result preliminarily shows that the fusion protein rHTA has good sustained-release effect and lower bleeding risk, which provides a basis for the fusion protein rHTA to release the anticoagulant components AnxV protein and Hirudin protein triggered by thrombin.

[0096] Example 3, phospholipid binding analysis of fusion protein rHTA

[0097] In order to verify whether the AnxV domain in the fusion protein rHTA retains its specific targeting binding function to phosphatidylserine (L-A-Phosphatidyl-L-serine, PS), enzyme-linked immunosorbent assay (ELISA) was used to evaluate the binding characteristics of the fusion protein rHTA to PS and phosphatidylcholine (L-α-Phosphatidylcholine, PC), and AnxV protein was used as a control. The specific steps are as follows:

[0098] 1. Take 96-well plates, and add 50 μL of chloroform solution containing 2.5 μg of PS or PC to each well, and stand for adsorption in the fume hood for 2 h.

[0099] 2. After completing step 1, sequentially perform blocking and washing, and then add the test protein (fusion protein rHTA or AnxV protein) with a concentration of 0.05 μg / mL, 0.10 μg / mL, 0.50 μg / mL, 1.00 μg / mL, 5.00 μg / mL, 10.00 μg / mL, 50.00 μg / mL or 100.00 μg / mL, and incubate at 37°C for 2 h.

[0100] 3. After completing step 2, add mouse anti-AnxV antibody (product of Abeam Company, product catalog number ab284810) as a primary antibody, incubate and wash; then add HRP-goat anti-mouse IgG antibody (product of Yixing Biotech (Shanghai) Co., Ltd., item number 31223ES60) as a secondary antibody, incubate and wash; finally, TMB coloration is used to terminate the reaction, and after standing for 5 min, the absorbance at 450 nm is detected by an enzyme label instrument.

[0101] The detection results are shown in Figure 3The results show that the binding of the fusion protein rHTA and PS shows a concentration-dependent trend, and as the concentration of the fusion protein rHTA increases, the absorbance at 450 nm also gradually increases (0.093±0.02 to 0.773±0.14); and the degree of binding with PC is basically unchanged, which shows that the fusion protein rHTA can bind with PS, but basically cannot bind with PC. Compared with the AnxV protein, the PS binding signal of the fusion protein rHTA in the range of 0.05-1.00 μg / mL is not significantly different, and the PS binding signal intensity in the range of 5.00-100.00 μg / mL is slightly higher.

[0102] It can be seen that the fusion protein rHTA retains the specific binding ability of the AnxV protein to PS.

[0103] Example 4, Effect of Fusion Protein rHTA on Plasma Coagulation Time

[0104] The effect of the fusion protein rHTA on plasma coagulation time was explored by plasma recalcification experiment. The specific steps are as follows:

[0105] 1. Take 96-well plates, and add 50 μL of chloroform solution containing 2.5 μg of PS to each well, and stand for adsorption in the fume hood for 2 h.

[0106] 2. After completing step 1, sequentially perform blocking and washing, and then add Binding Buffer (as a blank control group) or the protein to be tested (fusion protein rHTA, fusion protein HA, or AnxV protein) with a concentration of 0 μmol / L, 20 μmol / L, 40 μmol / L, or 80 μmol / L, and incubate at 37°C for 1 h, and then wash.

[0107] 3. After completing step 2, add 100 μL of 50% rat anemic platelet plasma (PPP) to each well, and incubate at 37°C for 3 min; then quickly add 25 μL of CaCl2 solution with a concentration of 0.08 M (final concentration 16 mM) to activate coagulation, and detect the absorbance at 405 nm every 1 min or 5 min using an enzyme marker.

[0108] Some of the test results are shown in Figure 4 The test results are as follows: the blank control group coagulates plasma after 30 min of calcium addition; in the fusion protein rHTA treatment group, the plasma coagulation time shows a trend of prolongation with the increase of the concentration, and the plasma coagulates at 50 min when the concentration is 20-40 μmol / L, and coagulates at 60 min when the concentration is 80 μmol / L, which shows that the fusion protein rHTA has a dose-dependent anticoagulant effect. In comparison, in the AnxV protein treatment group, the coagulation time does not significantly increase with the increase of the concentration, and the coagulation time is only 35 min when the concentration is 80 μmol / L; and when the protein concentration is the same, the coagulation time of the fusion protein HA treatment group is shorter than that of the fusion protein rHTA.

[0109] The above results show that the anticoagulant effect of the fusion protein rHTA is better than that of the single AnxV protein and the fusion protein HA without a cleavage site. The fusion protein rHTA realizes a multi-path cooperative anticoagulant effect through AnxV protein-mediated thrombus targeting enrichment and Hirudin activity release triggered by thrombin.

[0110] Example 5, Evaluation of the Effect of Fusion Protein rHTA on Thrombin

[0111] The S-2238 substrate is a product of Wuhan Haishengxinxian Biological Technology Co., Ltd., with product catalog number CAS 115388-96-0.

[0112] To detect whether the fusion protein rHTA can obtain better thrombin inhibition activity after being cleaved by thrombin, the substrate colorimetric method (Zhu Yujie. Anti-thrombotic effect of injectable hydroxysafflor yellow A by inhibiting platelet activation and thrombin activity [D]. Tianjin University of Traditional Chinese Medicine, 2023. DOI: 10.27368 / d.cnki.gtzyy.2023.000313.) was used to detect and compare the inhibition kinetic characteristics of the fusion protein rHTA, the fusion protein HA, and rHirudin on thrombin. The specific steps are as follows:

[0113] 1. Detection of the effect of the test protein (fusion protein rHTA, fusion protein HA, or rHirudin) on thrombin activity

[0114] Recombinant Hirudin (i.e., rHirudin) was purchased from Sino Biological company. The amino acid sequence of rHirudin is shown in SEQ ID NO: 4 from the 1st to the 66th amino acid from the N-terminal, i.e., the components of rHirudin are the same as those of Hirudin protein.

[0115] Mix 40 μL of the test protein (fusion protein rHTA, fusion protein HA, or rHirudin protein) sample with a concentration of 0 nM, 10 nM, 80 nM, or 160 nM and 40 μL of thrombin (concentration of 2 U / mL), and incubate at room temperature or 37°C for 3 min; then add 40 μL of S-2238 substrate with a concentration of 1 mg / mL, and react at room temperature for 15 min; finally, detect the absorbance at 405 nm using an enzyme marker. Analyze the thrombin activity and sample inhibition effect by the absorbance change at 405 nm.

[0116] 2. Analysis of the inhibition kinetics of thrombin activity

[0117] The inhibitory characteristics of fusion proteins rHTA and fusion protein HA on thrombin were compared using the Lineweaver-Burk double reciprocal plot method. 40 μL of the test protein (fusion protein rHTA or fusion protein HA) at concentrations of 0 nM, 10 nM, 80 nM, or 160 nM was mixed with 40 μL of thrombin (concentration 2 U / mL) and incubated at 37°C for 3 min. Then, different concentrations (160-800 nM) of S-2238 substrate were added, and the OD was monitored within 5 min using a microplate reader. 405nm The change is calculated, the initial rate (V0) is plotted with 1 / [S] as the X-axis and 1 / V0 as the Y-axis to determine the type of suppression, and the suppression constant (Ki) is calculated by fitting the quadratic plot.

[0118] The results are as follows: After incubation with thrombin at room temperature for 3 min, the antithrombin activity of the fusion protein rHTA was close to that of the fusion protein HA; however, after incubation at 37℃ for 3 min, the antithrombin activity of the fusion protein rHTA in the 80 nM and 160 nM groups was significantly activated in a concentration-dependent manner, and at high concentrations, the activity was close to that of hirudin. Figure 5 In the diagram, A represents the fusion protein rHTA, HA represents the fusion protein HA, the x-axis represents the concentration of the target protein, and the y-axis represents the residual thrombin activity. It is noteworthy that thrombin cleavage activates the protein with extremely high efficiency; at 37°C, only 3 minutes are needed to significantly increase the antithrombin activity of the rHTA fusion protein, approaching the level of a 3-hour cleavage. Therefore, thrombin cleavage can effectively improve the antithrombin activity of the rHTA fusion protein.

[0119] Furthermore, Lineweaver-Burk double reciprocal plotting analysis showed that both the fusion protein rHTA and the fusion protein HA are mixed thrombin inhibitors. Figure 5 In the diagram, B and HTA represent fusion proteins (rHTA and HA, respectively), but rHTA exhibits a more non-competitive inhibition pattern. The inhibition constant (Ki) of rHTA is 2.120 nM, while that of HA is 273.412 nM. This demonstrates that rHTA exhibits significantly higher inhibitory activity against thrombin than HA.

[0120] Example 6: Effect of fusion protein rHTA on activated partial thromboplastin time (APTT)

[0121] 1. Collect 3.2% sodium citrate anticoagulated whole blood (blood:ant = 9:1), centrifuge, and obtain anemic platelet plasma (PPP, platelet count < 10 × 10⁻⁶). 9 / L).

[0122] 2、After step 1, mix 50 μL of PPP and 10 μL of the solution to be tested (PBS buffer (as negative control), heparin with a concentration of 10 μM (as positive control), fusion protein rHTA with a concentration of 1 μM, fusion protein rHTA with a concentration of 5 μM, fusion protein rHTA with a concentration of 10 μM, fusion protein HA with a concentration of 1 μM, fusion protein HA with a concentration of 5 μM, or fusion protein HA with a concentration of 10 μM), and then add 100 μL of APTT reagent (product of Sun Bio Technology (Hangzhou) Co., Ltd., product catalog number APTT-E-01) preheated to 37°C into a PCR tube, and incubate at 37°C for 3 minutes.

[0123] 3、After step 2, start the reaction: add 50 μL of 0.025 mol / L calcium ion solution preheated to 37°C, mix immediately and start timing. Monitor the whole process of the reaction, and stop timing immediately when white flocculent substances are produced.

[0124] The detection results are shown in Table 1. Figure 6 (ctrl is the negative control, HTA is fusion protein rHTA, and HA is fusion protein HA). The detection results show that both fusion protein rHTA and fusion protein HA can significantly prolong the activated partial thromboplastin time; compared with fusion protein HA, the prolonging effect of fusion protein rHTA is more obvious, that is, the inhibitory effect on the in vivo blood coagulation pathway is stronger.

[0125] Example 7, platelet binding experiment

[0126] 1、Add 90 parts of sodium citrate solution with a concentration of 106 mM to 10 parts of blood, and centrifuge at 180 g for 10 minutes to obtain platelet-rich plasma; then wash twice with buffer C (solute and its concentration: 10 mM HEPES, 136 mM NaCl, 2.68 mM KCl, 2 mM MgCl2, 25 mM glucose, 0.5% BSA, solvent: water, pH 6.6) and resuspend in buffer D (solute and its concentration: 10 mM HEPES, 136 mM NaCl, 2.68 mM KCl, 2 mM MgCl2, 25 mM glucose, 0.5% bovine serum albumin, solvent: water, pH 7.5) to obtain a platelet suspension with a concentration of 3 x 10 8

[0127] 2、After step 1, add thrombin (2 U / mL) and HBS-Ca 2+ to the platelet suspension, and activate the platelets at 37°C for 15 minutes. Then mix the activated platelets with FITC-labeled fusion protein rHTA or fusion protein HA with a concentration of 10 nM, 200 nM or 1000 nM at 37°C for 2 hours, and avoid light.​

[0128] 3. After step 2, the fluorescence intensity of the platelets was immediately detected using a FACSCalibur flow cytometer (Becton Dickinson, San Jose, CA, USA) and analyzed using CellQuest software.

[0129] According to the above steps, step 2 is replaced by step 2A, and other steps remain unchanged, to obtain control 1. Step 2A is: at 37°C, the platelet suspension is mixed with FITC-labeled fusion protein rHTA or fusion protein HA at a concentration of 10 nM, 200 nM or 1000 nM for 2 hours, and avoid light.

[0130] According to the above steps, step 2 is replaced by step 2B, and other steps remain unchanged, to obtain control 2. Step 2B is: thrombin (2 U / mL) and HBS-Ca 2+ are added to the platelet suspension, and the platelets are activated at 37°C for 15 min. Then, the platelets are placed at 37°C for 2 hours in the dark.

[0131] Some of the test results are shown in Table 1 Figures 7-13 (HTA is fusion protein rHTA, HA is fusion protein HA, control is control 1), and the analysis and statistical results are shown in Table 2 Figure 14 (ctrl1 is control 1, ctrl2 is control 2, HTA is fusion protein rHTA, HA is fusion protein HA, and the data is expressed as mean ± standard deviation (n = 3)). The results show that both fusion protein rHTA and fusion protein HA can effectively bind to activated platelets, and show an effective dose-dependent effect; but there is no significant difference between the two at the three concentration intervals. Compared with fusion protein HA, fusion protein rHTA shows stronger binding capacity to activated platelets, which reveals that fusion protein rHTA can more effectively target activated platelets at the thrombus formation site in vivo, thereby showing the thrombin-oriented specific anticoagulation effect.

[0132] The above results show that fusion protein rHTA has the potential to exert multi-pathway synergistic anticoagulation in vivo, while achieving high anticoagulation efficiency and low bleeding risk.

[0133] The above has been described in detail. For those skilled in the art, without departing from the purpose and scope of the present application, and without unnecessary experiments, the present application can be implemented in a wide range of equivalent parameters, concentrations and conditions. Although the present application gives a special example, it should be understood that further improvements can be made to the present application. In general, according to the principle of the present application, this application intends to include any change, use or improvement of the present application, including changes made by conventional techniques known in the art, which are outside the scope disclosed in the present application.

Claims

1. Fusion protein, consisting of Hirudin protein, thrombin cleavage site, and AnxV protein from N-terminus to C-terminus; The amino acid sequence of the Hirudin protein is shown in SEQ ID NO:4 from position 1 to 66 starting from the N-terminus; The amino acid sequence of the AnxV protein is shown in SEQ ID NO:4 from position 73 to 393 starting from the N-terminus.

2. The fusion protein according to claim 1, characterized in that: The amino acid sequence of the thrombin cleavage site is shown in SEQ ID NO:4 from position 67 to 72 starting from the N-terminus.

3. The fusion protein according to claim 2, characterized in that: The fusion protein is a1), a2), or a3): a1) The amino acid sequence of the protein is shown in SEQ ID NO:4 from position 1 to 393 starting from the N-terminus; a2) A fusion protein obtained by attaching a tag to the N-terminus and / or C-terminus of the protein shown in a1); a3) Proteins obtained by substituting and / or deleting and / or adding one or more amino acid residues, as shown in a1) or a2), that have anticoagulant, thrombin-inhibiting, antithrombin-enhancing and / or thrombotic disease-preventing effects.

4. A nucleic acid molecule encoding any of the fusion proteins of claims 1 to 3.

5. The nucleic acid molecule according to claim 4, characterized in that: The nucleotide sequence encoding the Hirudin protein is shown in SEQ ID NO:1 from position 1 to 198 starting from the 5' end; The nucleotide sequence encoding the AnxV protein is shown in SEQ ID NO:1 from position 217 to 1179 starting from the 5' end; The nucleotide sequence encoding the thrombin cleavage site is shown in SEQ ID NO:1 from position 199 to 216 starting from the 5' end.

6. An expression cassette, recombinant vector, or recombinant microorganism containing the nucleic acid molecule of claim 4 or 5.

7. The use of any of the fusion proteins of claims 1 to 3, the nucleic acid molecules of claims 4 or 5, or expression cassettes containing the nucleic acid molecules of claims 4 or 5, recombinant vectors, or recombinant microorganisms in the preparation of the product; wherein the product functions as anticoagulation, inhibition of thrombin, enhancement of antithrombin activity, and / or prevention of thrombotic diseases.

8. The application according to claim 7, characterized in that: The product is a medicine.

9. The use of the fusion protein according to any one of claims 1 to 3 as a thrombin inhibitor or anticoagulant.

10. The use of the nucleic acid molecule of claim 4 or 5, or an expression cassette, recombinant vector, or recombinant microorganism containing the nucleic acid molecule of claim 4 or 5, in the preparation of thrombin inhibitors or anticoagulants.

Citation Information

Cited By

  • Anticoagulant fusion protein HSA-Qinghaenin (c) and coding gene and application thereof

    CN121378515A